KWM has advised client Agalimmune Ltd, a private UK-based company with an innovative, anti-cancer immunotherapy platform, on the acquisition by BioLineRx Ltd, a clinical-stage biopharmaceutical company focused on oncology and immunology.

The acquisition consideration consisted of an upfront payment in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.

Agalimmune’s lead compound harnesses the body’s pre-existing anti-alpha-Gal antibodies to induce a systemic, specific anti-tumour response to the patient’s own tumour neo-antigens, not only killing the tumour cells at the site of injection but also bringing about a durable, follow-on immune response.

The KWM team comprised of Consultant Andrew Shindler, Corporate Partner Greg Stonefield, Corporate Counsel Barri Mendelsohn and Managing Associate Jack Tsang.

Andrew Shindler stated "We are delighted to have worked with Agalimmune and its purchaser, BioLineRx, on this exciting transaction which has great promise in the treatment of cancer. Both teams showed a great collaborative spirit throughout the deal which was completed in a challenging time-frame."

Damian Marron, CEO of Agalimmune added, "We are very excited that we found an ideal partner for our unique platform and we look forward to its accelerated clinical development by BioLineRx. The KWM team provided excellent advice and support throughout the deal."